Navigation Links
NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Date:10/31/2007

g postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy. NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the company believes offers significant advantages over other pain therapies. Three Phase 3 clinical trials with NGX-4010 have been completed and have met their primary endpoints, two in PHN and one in painful HIV-DSP.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the timing of presentations by NeurogesX and the expected benefits of NeurogesX' potential products, including its lead product candidate NGX-4010. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, past results of clinical trials may not be indicative of future clinical trials results; NeurogesX' product candidate may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; physician or patient reluctance to use NGX-4010, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in clinical development, obtaining regulatory approval, market acceptance and commercialization of NGX-4010
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") today announced results ... 2015 first quarter financial statements and MD&A have been filed on ... March 31,(in CDN$,000 except per share data) , 2015 ... Gross profit , 1,531 , 329 Ebitda* , ... 528 , (531) Basic earnings (loss) per share ...
(Date:6/1/2015)... 01, 2015 Regis Technologies, Inc. ... of chiral stationary phases (CSPs) for analytical and ... current and presenting solutions for new clients, Regis ... This valuable addition to its core expertise in ... that can tackle projects for the scale clients ...
(Date:6/1/2015)... -- Neogen Corporation (NASDAQ: NEOG ) announced today that it ... commercial food testing laboratory based in southwest India ... a base for the company,s new operations in ... was incorporated in 1990, and its business has grown ... quality testing for major hotels and restaurants in its home ...
(Date:6/1/2015)... 2015 Esperance Pharmaceuticals Inc. today reported positive ... EP-100 in ovarian cancer patients resistant to paclitaxel. EP-100 ... destroy cancer cells that overexpress luteinizing hormone-releasing hormone (LHRH) ... a wide range of cancers. Results ... EP-100 were presented at the 2015 ASCO Annual ...
Breaking Biology Technology:Biorem Reports Increased Revenues and Earnings for First Quarter 2Biorem Reports Increased Revenues and Earnings for First Quarter 3Regis Technologies Offers Chiral Chromatography Service 2Regis Technologies Offers Chiral Chromatography Service 3Neogen acquires India food safety company 2Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 2Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 3
... Inc., a privately held,biopharmaceutical company focused on ... today announced a company,restructuring that includes the ... significant reduction in work force, primarily in ... company,s burn rate and refocuses,Sangart,s business units ...
... 7 GlaxoSmithKline plc (LSE/NYSE: GSK ) ... by its wholly-owned subsidiary Gemstone Acquisition Corporation for shares ... GNLB ). The tender offer expired at 12:00 ... 2009.The depositary for the tender offer has advised GSK ...
... REDWOOD CITY, Calif., Jan. 7 Codexis, Inc. today ... produce an,important publicly-undisclosed generic product, using a proprietary Codexis,biocatalyst. ... world, is a,leading producer of this generic product. ... drugs in the United States. , ...
Cached Biology Technology:Sangart, Inc. Announces Key Executive Appointments and Company Restructuring 2Sangart, Inc. Announces Key Executive Appointments and Company Restructuring 3GlaxoSmithKline Successfully Completes Tender Offer for Shares of Genelabs Technologies, Inc. 2Codexis, Teva in Licensing Agreement Final 2
(Date:5/19/2015)... May 19, 2015 ... the addition of the  "Genetic Testing Market ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic ... analysis of the current and future genetic ... tests, their working principles and types are ...
(Date:5/14/2015)... 14, 2015 Research and Markets ( ... "Fingerprint Sensors Market in Smart Mobile Devices " ... that 2014 was a watershed year for fingerprint sensors ... ,Apple Pay,. Apple gave fingerprint sensors a raison d,etre ... Fingerprint sensors are a must-have feature in flagship smartphones. ...
(Date:5/11/2015)... Calif. , May 11, 2015  Synaptics ... of human interface solutions, today announced the appointment ... President and Chief Financial Officer, reporting to ... replaces Synaptics, current Chief Financial Officer, Kathleen ... 2014. Mr. Ali brings extensive ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... vaccine that enlists help from the immune system to keep ... to help smokers quit and to limit the urge to ... being developed by Nabi Biopharmaceuticals to prevent and treat nicotine ... smoker inhales, nicotine is carried by the bloodstream to the ...
... Scientists at the Albert Einstein College of Medicine of ... gene expression can occur in the form of discrete ... techniques, developed by Dr. Robert Singer and colleagues at ... directly watch the behavior of a single gene in ...
... subpopulation of helper T-cells provides immunity and promotes survival ... means of predicting an AIDS vaccine's effectiveness, a discovery ... in clinical trials. , Led by researchers at Beth ... Center (VRC) at the National Institute of Allergy and ...
Cached Biology News:Einstein researchers take the pulse of a gene in living cells 2AIDS vaccine research offers new insights on survival 2AIDS vaccine research offers new insights on survival 3
X-gal,1g...
Standard 2" or 3" Plastic can be ordered with 81 or 100 cell dividers. Mini 2" Plastics Boxes come standard with 25 cell dividers. Plastic boxes can also be ordered with corresponding freezer racks...
... Conjugation, Quantities to Kilograms, ... Special amino acids and their ... labeling AMC, aldehyde, CMK, Purity ... Chromogenic/Flurogenic Substrates, Solid Phase/Solution/Segment ...
... The Gla-type Osteocalcin EIA Kit is ... kit for quantitative determination of human ... cell culture supernatants, and other biological ... research use only. It is not ...
Biology Products: